Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2012, Article ID 576584, 7 pages
Clinical Study

HOMA-AD in Assessing Insulin Resistance in Lean Noncirrhotic HCV Outpatients

Gastroenterology Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos 2350, 90035-003 Porto Alegre, RS, Brazil

Received 27 February 2012; Revised 22 May 2012; Accepted 22 May 2012

Academic Editor: Claudia Oliveira

Copyright © 2012 Matheus Truccolo Michalczuk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. There is an association between HCV and insulin resistance (IR), which is currently assessed by HOMA-IR. There is evidence that HOMA-adiponectin (HOMA-AD) is more accurate, but its role in HCV patients is unknown. The purpose of this study was to evaluate IR in an HCV sample and controls, in order to compare the accuracy of HOMA-IR and HOMA-AD. Methods. Ninety-four HCV outpatients aged <60 years who met the criteria of nondiabetic, nonobese, noncirrhotic, and nonalcohol abusers were included and compared to 29 controls. Fasting glucose, insulin, adiponectin, and lipid profiles were determined. IR was estimated by HOMA-IR and HOMA-AD. Results. The groups were similar regarding sex and BMI, but the HCV patients were older. The median insulin level was higher in the HCV group (8.6 mU/mL (6.5–13.7) versus 6.5 (4.3–10.7), ), as was median HOMA-IR (1.94 (1.51 to 3.48) versus 1.40 (1.02 to 2.36), ) and the prevalence of IR (38.3% versus 10.3% ( )). No differences were found in adiponectin levels ( ) and HOMA-AD ( ). Conclusion. IR is highly prevalent even in low-risk HCV outpatients. Adiponectin is not influenced by the presence of HCV. HOMA-AD does not seem to be useful in assessing IR in HCV patients.